Mesenchymal Stem Cells as Therapeutics

By Biju Parekkadan, J. Milwid. Annual Review of Biomedical Engineering, 2010

731 citations recorded by the source corpus.

Mesenchymal stem cells (MSCs) are multipotent cells that are being clinically explored as a new therapeutic for treating a variety of immune-mediated diseases. First heralded as a regenerative therapy for skeletal tissue repair, MSCs have recently been shown to modulate endogenous tissue and immune cells. Preclinical studies of the mechanism of action suggest that the therapeutic effects afforded by MSC transplantation are short-lived and related to dynamic, paracrine interactions between MSCs and host cells. Therefore, representations of MSCs as drug-loaded particles may allow for pharmacokinetic models to predict the therapeutic activity of MSC transplants as a function of drug delivery mode. By integrating principles of MSC biology, therapy, and engineering, the field is armed to usher in the next generation of stem cell therapeutics.

Subfields: Biomaterials, Genetics, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/cb73063542032f4b61f67bf2b4425463b9decf5d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. H. Yagi
2. M. Islam
3. A. Soto‐Gutierrez
4. Shonita Das
5. M. Emin
6. Y. Kitagawa
7. M. Yarmush
8. M. Wei

Citations in the corpus

• Mesenchymal Stem Cells: Mechanisms of Immunomodulation and Homing (2010, background): “However, a considerable amount of data suggest improved outcomes after transplantation even in the absence of apparent MSC long-term engraftment [ 11 ] .”
• Mitochondrial transfer from bone marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury (2012, background): “Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production.”